Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$1.37
-$0.01(-0.78%)
At close: 4:00 PM EDT
$1.37
-$0.01(-0.78%)
Day’s Range― - ―
52-Week Range$1.17 - $13.25
Previous CloseN/A
Volume62.46K
Average Volume (3M)67.98K
Market Cap
$6.18M
Enterprise Value-$2.79M
Total Cash (Recent Filing)$8.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.46
Shares Outstanding4,475,884
10 Day Avg. Volume68,615
30 Day Avg. Volume67,978
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.15
Enterprise Value/Ebitda0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Minimal DebtMinimal debt reduces interest expense and refinancing exposure, giving Enveric greater flexibility while it advances its development programs. This relatively low-leverage position can help preserve capital for research and limit the financial strain that borrowing would create during ongoing losses.
Improved Equity BaseThe improvement in equity provides a stronger capitalization base than in 2025 and may support continued operations over the medium term. Although equity has been volatile historically, the latest increase is a constructive balance-sheet development for a clinical-stage company.
Reduced Historical LossesLower losses than in earlier years suggest some expense discipline and a more controlled operating structure. That improvement does not establish profitability, but it could help extend the company’s development runway and moderate the pace of funding required if maintained.
Bears Say
No Commercial RevenueThe absence of revenue means Enveric has no commercial sales base to fund research, administration, or future clinical development. Until a candidate reaches commercialization or another revenue source emerges, the business remains dependent on capital markets or strategic funding.
Persistent Cash BurnA substantial and recurring cash outflow reduces financial flexibility and requires continued funding while the company remains pre-revenue. The re-acceleration from 2025 to TTM indicates that improved historical spending control has not yet eliminated the need for external capital.
Large Ongoing LossesLarge net losses and negative gross profit show that the current cost base is not supported by operating income. This limits internally generated investment capacity and keeps profitability distant, increasing the importance of successful development outcomes and disciplined spending.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.17 and its highest was $13.25 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $6.18M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 24 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.759 earnings per share for the quarter.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$0.759 in its last earnings report. Following the earnings report the stock price went down -3.583%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
13.67% Insiders
0.18% Mutual Funds
8.03% Other Institutional Investors
76.87% Public Companies and
Individual Investors